Mylan NV (MYL)-Financial and Strategic SWOT Analysis Review
March 2017
68
About the Report
About the Report
Mylan NV (MYL)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
Business description-A detailed description of the company's operations and business divisions.
Corporate strategy-Analyst's summarization of the company's business strategy.
SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.
Company history-Progression of key events associated with the company.
Major products and services-A list of major products, services and brands of the company.
Key competitors-A list of key competitors to the company.
Key employees-A list of the key executives of the company.
Executive biographies-A brief summary of the executives' employment history.
Key operational heads-A list of personnel heading key departments/functions.
Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.
Key manufacturing facilities-A list of key manufacturing facilities of the company.
Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Mylan NV (Mylan) is a pharmaceutical company, which focuses on development, licensing, manufacture, marketing and distribution of generics, branded medicines and consumer healthcare products. It offers pharmaceutical products in multiple forms across therapeutic categories such as respiratory and allergy, cardiovascular, central nervous systems, infectious disease, oncology, anesthesia and others. Mylan sells its products to retail pharmacy chains, wholesalers and distributors, group purchasing organizations, drug store chains, independent pharmacies, drug manufacturers, institutions, and public and governmental agencies. It has operations in the US and Canada, Europe, the Middle East and Africa, and India, Australia, Japan, New Zealand and Brazil. Mylan is headquartered in Hatfield, Hertfordshire, the UK.
Mylan NV Key Recent Developments
Mar 01,2017: Mylan Reports Fourth Quarter and Full Year 2016 Results and Provides 2017 Guidance
Nov 29,2016: New ADEKplus a Fat Soluble Nutritional Product Launched to Aid Conditions Such as Cystic Fibrosis
Nov 09,2016: Mylan Reports Third Quarter 2016 Results
Aug 25,2016: Teva Plunges After Two U.S. Copaxone Patents Invalidated
Aug 09,2016: Mylan Reports Strong Second Quarter 2016 Results Including Total Revenues Up 8%
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Products
Products
Mylan NV, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts
Companies
Versartis IncTeva Pharmaceutical Industries LtdRegeneron Pharmaceuticals IncPar Pharmaceutical Holdings IncNovartis Pharma AGMerck & Co IncMallinckrodt PlcGlaxoSmithKline PlcEndo International PlcEli Lilly and CompanyBristol-Myers Squibb CompanyAllergan Plc
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Section 1-About the Company 6
Mylan NV-Key Facts 6
Mylan NV-Key Employees 7
Mylan NV-Key Employee Biographies 8
Mylan NV-Major Products and Services 9
Mylan NV-Pharmaceutical Pipeline Products Data 10
Mylan NV, Pipeline Products by Therapy Area 10
Mylan NV, Pipeline Products by Development Phase 10
Mylan NV-History 12
Mylan NV-Company Statement 23
Mylan NV-Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Section 2-Company Analysis 31
Mylan NV-Business Description 31
Mylan NV-SWOT Analysis 32
SWOT Analysis-Overview 32
Mylan NV-Strengths 32
Mylan NV-Weaknesses 33
Mylan NV-Opportunities 34
Mylan NV-Threats 35
Mylan NV-Key Competitors 36
Section 3-Company Financial Ratios 37
Financial Ratios-Capital Market Ratios 37
Financial Ratios-Annual Ratios 38
Performance Chart 40
Financial Performance 40
Financial Ratios-Interim Ratios 41
Financial Ratios-Ratio Charts 42
Section 4-Company's Lifesciences Financial Deals and Alliances 43
Mylan NV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 43
Mylan NV, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 44
Mylan NV, Recent Deals Summary 45
Section 5-Company's Recent Developments 46
Mar 01, 2017: Mylan Reports Fourth Quarter and Full Year 2016 Results and Provides 2017 Guidance 46
Nov 29, 2016: New ADEKplus a Fat Soluble Nutritional Product Launched to Aid Conditions Such as Cystic Fibrosis 48
Nov 09, 2016: Mylan Reports Third Quarter 2016 Results 49
Aug 25, 2016: Teva Plunges After Two U.S. Copaxone Patents Invalidated 53
Aug 09, 2016: Mylan Reports Strong Second Quarter 2016 Results Including Total Revenues Up 8% 55
Jun 23, 2016: Mylan Donates EUR1 Million to the Princess Maxima Center for Pediatric Oncology 58
May 03, 2016: Mylan Names Kenneth Parks Chief Financial Officer 59
May 03, 2016: Mylan Reports Strong First Quarter 2016 Earnings Results Including Total Revenues Up 17% 60
Feb 22, 2016: Mylan Appoints Anthony Mauro Chief Commercial Officer 62
Feb 22, 2016: Mylan CEO Heather Bresch Elected Chair of Generic Pharmaceutical Association 63
Section 6-Appendix 64
Methodology 64
Ratio Definitions 64
About GlobalData 68
Contact Us 68
Disclaimer 68
List of Figure
List of Tables
Mylan NV, Key Facts 6
Mylan NV, Key Employees 7
Mylan NV, Key Employee Biographies 8
Mylan NV, Major Products and Services 9
Mylan NV, Number of Pipeline Products by Development Stage 11
Mylan NV, History 12
Mylan NV, Other Locations 25
Mylan NV, Subsidiaries 26
Mylan NV, Key Competitors 36
Mylan NV, Ratios based on current share price 37
Mylan NV 38
Mylan NV (Cont...1) 39
Mylan NV, Interim Ratios 41
Mylan NV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 43
Mylan NV, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 44
Mylan NV, Recent Deals Summary 45
Currency Codes 64
Capital Market Ratios 64
Equity Ratios 65
Profitability Ratios 65
Cost Ratios 66
Liquidity Ratios 66
Leverage Ratios 67
Efficiency Ratios 67
List of Table
List of Figures
Mylan NV, Pipeline Products by Therapy Area 10
Mylan NV, Pipeline Products by Development Phase 10
Mylan NV, Performance Chart (2012-2016) 40
Mylan NV, Ratio Charts 42
Mylan NV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 43
Mylan NV, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 44
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.